Table 2 Synopsis of randomized control trials carried out in outpatient or outpatient/ED setting evaluated by metanalysis included in the updated version of the Italian bronchiolitis guidelines 2022
From: Bronchiolitis guidelines: what about the Italian situation in a primary care setting?
Study | Patients’ n. | Patients’ age | Setting | Viral typing | Severity | Active treatment | Outcomes |
|---|---|---|---|---|---|---|---|
Gupta, 2008 [36] | 140 | < 12 m | OUT | RSV & O | Mild | Oral salbutamol | Time to illness resolution |
Schuh, 1990 [40] | 40 | < 24 m | OUT | RSV & O | n.a. | Nebulized albuterol | Improvement in accessory muscle score, RR and O2 saturation |
Alario, 1992 [37] | 74 | < 36 m | OUT | RSV & O | Mild | Nebulized metaproterenol sulfate | Variation of HR, RR, O2 saturation |
Gadomski, 1994 [34] | 88 | < 12 m | OUT/ED | RSV & O | n.a. | Nebulized and oral albuterol | Variation of RR and HR, clinical score, O2 saturation (T0’, T30’, T60’) |
Gadomski, 1994 [35] | 128 | < 12 m | OUT/ED | RSV & O | n.a. | Nebulized and oral albuterol | Variation of RR and HR, clinical score, and O2 saturation |
Kuyucu, 2004 [19] | 69 | < 24 m | OUT/ED | n.a. | Mild-moderate | Intramuscular dexametasone | Variation of HR, RDAI score (T30’, T60’, T90’, T120’; 24 h and 5 days) |